By RYOSUKE NONAKA/ Staff Writer
October 1, 2021 at 17:40 JST
The Asahi Shimbun
A Kyoto University-led research team said its studies on iPS cells pinpointed a medicine that halted the progression of amyotrophic lateral sclerosis (ALS) in patients for the first time in the world.
The researchers on Sept. 30 said their finding cannot yet be labeled a cure for ALS, given the small sample size in the clinical tests, but it does raise hopes of saving people from the neurodegenerative disease.
“We had only a small number of test subjects,” said team member Haruhisa Inoue, a professor of neuroscience stem cell medicine at Kyoto University’s Center for iPS Cell Research and Application. “But there is now a higher possibility that science can beat (ALS).”
ALS, also known as Lou Gehrig’s disease, causes a loss of motor neurons. Muscles can then waste away, leading to difficulties in moving and eventually an inability to breathe.
Inoue and the other researchers reproduced the disease through iPS cells derived from patients’ skin.
They tested existing medicines that were designed for other illnesses on the sick cells, and found that Bosutinib, a drug for leukemia patients, was the most promising.
Nine ALS patients took 100 to 300 mg of Bosutinib per day for 12 weeks. ALS progression stopped in five of them.
“What happened was a phenomenon not normally seen,” Inoue said.
But the disease progressed at its usual pace for the four other patients.
One patient who took 400 mg per day developed a liver disorder, so the medication was stopped. Leukemia patients who have taken Bosutinib have also suffered from that side effect.
The test subjects were all in the early stages of progressive ALS development.
The clinical tests were conducted mainly to ensure the safety of Bosutinib, so the team could not judge statistically whether the medicine was effective against ALS.
The team plans to conduct larger clinical tests to determine the drug’s effectiveness, the possible side effects, which patients should receive the medicine, and the proper doses.
About 9,000 people in Japan have ALS.
Existing treatments can slow down the progression of ALS, but no cure has been found.
Parkinson’s drug helps treat ALS, trial using iPS cells discovers
May 21, 2021
Cancer patient treated with iPS cells for first time in Japan in trial
October 23, 2020
Groundbreaking eye surgery in Kobe offers hope to sight impaired
October 17, 2020
Brain invasions by coronavirus causing memory loss, other issues
November 30, 2020
Japan joins with Asian partners to fast-track cancer drug production
October 5, 2020
Nobel laureate calls for research funds to solve the mystery of aging
May 25, 2021
Stories about memories of cherry blossoms solicited from readers
Cooking experts, chefs and others involved in the field of food introduce their special recipes intertwined with their paths in life.
A series based on diplomatic documents declassified by Japan’s Foreign Ministry
A series on the death of a Japanese woman that sparked a debate about criminal justice policy in the United States
A series about Japanese-Americans and their memories of World War II
Here is a collection of first-hand accounts by “hibakusha” atomic bomb survivors.
